Practical guidelines for multiplicity adjustment in clinical trials

Citation
Ma. Proschan et Ma. Waclawiw, Practical guidelines for multiplicity adjustment in clinical trials, CONTR CL TR, 21(6), 2000, pp. 527-539
Citations number
21
Categorie Soggetti
Pharmacology,"Medical Research General Topics
Journal title
CONTROLLED CLINICAL TRIALS
ISSN journal
01972456 → ACNP
Volume
21
Issue
6
Year of publication
2000
Pages
527 - 539
Database
ISI
SICI code
0197-2456(200012)21:6<527:PGFMAI>2.0.ZU;2-2
Abstract
Multiplicity in clinical trials may appear under several different guises: multiple endpoints, multiple treatment arm comparisons, and multiple looks at the data during interim monitoring, to name a few. It is well recognized by statisticians and nonstatisticians alike that multiplicity inflates the type I error rate of the experiment, and this has prompted the development of many multiple comparison adjustment procedures. What has remained one o f the thornier and more controversial points of contention among trialists today is the philosophy surrounding the need for multiplicity adjustment in clinical trials. This paper provides guidelines on how to deal with this c omplex issue in a practical manner. Through a series of scenarios and examp les, we illustrate the fundamental issues surrounding the concept of multip licity and point to some key questions one should ask when deliberating on the necessity and extent of adjustment for multiple comparisons. (C) Elsevi er Science Inc. 2000.